Alternative Dosing Regimens of Subcutaneous Azacitidine for Myelodysplastic Syndromes
A Multicenter, Randomized, Open-Label Study Comparing Three Alternative Dosing Regimens of Subcutaneous Azacitidine Plus Best Supportive Care for the Treatment of Myelodysplastic Syndromes
研究概览
详细说明
Comparison/Control Interventions: The comparison is azacitidine at different doses and schedules.
Duration of Intervention: Treatment lasted for a maximum of 18 cycles, which is up to 24 months.
研究类型
注册 (实际的)
阶段
- 阶段2
联系人和位置
学习地点
-
-
California
-
Bakersfield、California、美国、93309
- Comprehensive Blood and Cancer Center, Research Department
-
Beverly Hills、California、美国、90211
- Tower Cancer Research Foundation
-
-
Colorado
-
Colorado Springs、Colorado、美国、80907
- Cancer Center of Colorado Springs, The Oncology Clinic, PC
-
Denver、Colorado、美国、80218
- Rocky Mountain Cancer Centers, LLP
-
-
District of Columbia
-
Washington、District of Columbia、美国、20010
- Washington Cancer Institute
-
-
Florida
-
New Port Richey、Florida、美国、34652
- Florida Cancer Institute
-
Ocoee、Florida、美国、34761
- Cancer Centers of Florida, P.A.
-
-
Illinois
-
Joliet、Illinois、美国、60435
- Joliet Oncology-Hematology Associates, Ltd.
-
Peoria、Illinois、美国、61615-7828
- Oncology/Hematology Associates of Central Illinois, PC
-
-
Indiana
-
Indianapolis、Indiana、美国、46227
- Central Indiana Cancer Centers
-
-
Louisiana
-
Metairie、Louisiana、美国、70115
- Hematology & Oncology Specialists LLC
-
-
Michigan
-
Lansing、Michigan、美国、48910
- Great Lakes Cancer Institute Breslin Cancer Center
-
-
Missouri
-
Saint Louis、Missouri、美国、63141
- The Center for Cancer Care and Research
-
-
New Jersey
-
Hackensack、New Jersey、美国、07601
- Hackensack University Medical Center
-
-
Ohio
-
Kettering、Ohio、美国、45409
- Greater Dayton Cancer Center
-
-
Pennsylvania
-
Pittsburgh、Pennsylvania、美国、15224
- Western Pennsylvania Cancer Institute
-
-
South Dakota
-
Aberdeen、South Dakota、美国、57401
- Oncology Services of Aberdeen
-
Sioux Falls、South Dakota、美国、57105
- Avera Cancer Institute Leukemia-Bone Marrow Transplant Center
-
-
Tennessee
-
Johnson City、Tennessee、美国、37604
- McLeod Cancer and Blood Center
-
Nashville、Tennessee、美国、37203
- The Sarah Cannon Research Institute
-
-
Texas
-
Bedford、Texas、美国、76022
- Texas Oncology, P.A.
-
Dallas、Texas、美国、75230
- Texas Cancer Center at Medical City
-
Fort Worth、Texas、美国、76104
- Texas Oncology, PA
-
Fredericksburg、Texas、美国、78624
- San Antonio Tumor & Blood Clinic
-
San Antonio、Texas、美国、78229
- Cancer Care Centers of South Texas - HOAST
-
-
Virginia
-
Norfolk、Virginia、美国、23502
- Virginia Oncology Associates - Lake Wright Cancer Center
-
-
Washington
-
Burien、Washington、美国、98166
- Highline Medical Oncology
-
Edmonds、Washington、美国、98026
- Puget Sound Cancer Center
-
Seattle、Washington、美国、98133
- Puget Sound Cancer Center
-
Spokane、Washington、美国、99218
- Cancer Care Northwest
-
Vancouver、Washington、美国、98684
- Northwest Cancer Specialists, P.C.
-
-
参与标准
资格标准
适合学习的年龄
接受健康志愿者
有资格学习的性别
描述
Inclusion Criteria:
- Diagnosis of refractory anemia, refractory anemia with ringed sideroblasts and at least one of the following: a)Anemia with hemoglobin <110g/L and requires at least 1 unit packed red blood cell transfusions every 28 days; b)Thrombocytopenia with platelet counts <100 x 10^9/L; or c)Neutropenia with absolute neutrophil count <1.5 x 10^9/L.
- OR, Refractory anemia with excess blasts or refractory anemia with excess blast in transformation, according to the French-American-British classification system for MDS.
- At least 18 years of age.
- Have a life expectancy of >7 months.
- Unlikely to proceed to bone marrow or stem cell transplantation therapy following remission.
- Have serum bilirubin levels less than or equal to 1.5 times the upper limit of the normal (ULN) range for the laboratory.
- Have serum glutamic-oxaloacetic transaminase (aspartate aminotransferase) or serum glutamic-pyruvic transaminase (alanine aminotransferase) levels less than or equal to 2 x ULN.
- Have serum creatinine levels less than or equal to 1.5 x ULN.
Exclusion Criteria:
- Secondary MDS.
- Prior treatment with azacitidine.
- Any prior history of Acute Myeloid Leukemia (AML).
- Malignant or metastatic disease within the previous 12 months.
- Uncorrected red cell folate deficiency or vitamin B12 deficiency.
- Hepatic tumors.
- Radiation, chemotherapy, or cytotoxic therapy for non-MDS conditions in the previous 12 months.
- Known or suspected hypersensitivity to azacitidine or mannitol.
- Prior transplantation or cytotoxic therapy to treat MDS. Prior use of Revlimid and Thalomid allowed after 30 day washout.
- Serious medical illness likely to limit survival to less than or equal to 7 months.
- Treatment with androgenic hormones during the previous 14 days
- Active viral infection with known human immunodeficiency virus or vial hepatitis Type B or C.
- Treatment with other investigational drugs with the previous 30 days.
学习计划
研究是如何设计的?
设计细节
- 主要用途:治疗
- 分配:随机化
- 介入模型:并行分配
- 屏蔽:无(打开标签)
武器和干预
参与者组/臂 |
干预/治疗 |
|---|---|
|
实验性的:Aza-5
Azacitidine administered subcutaneously at 75mg/m^2 for 5 days on a 28 day cycle.
|
Azacitidine is administered subcutaneously Total of 18 cycles on treatment or early discontinuation. |
|
实验性的:Aza-5-2-2
Azacitidine administered subcutaneously at 75mg/m^2 for 5days with 2 days off, then for an additional 2 days, on a 28 day cycle.
|
Azacitidine is administered subcutaneously Total of 18 cycles on treatment or early discontinuation. |
|
实验性的:Aza-5-2-5
Azacitidine administered subcutaneously at 50mg/m^2 for 5 days with 2 days off, then for an additional 5 days, on a 28 day cycle.
|
Azacitidine is administered subcutaneously Total of 18 cycles on treatment or early discontinuation. |
|
实验性的:Maintenance Aza 5 days q 4 weeks
Azacitidine administered subcutaneously at 75mg/m^2 for 5 days every 4 weeks.
|
Azacitidine is administered subcutaneously Total of 18 cycles on treatment or early discontinuation. |
|
实验性的:Maintenance Aza 5 days q 6 weeks
Azacitidine administered subcutaneously at 75mg/m^2 for 5 days every 6 weeks.
|
Azacitidine is administered subcutaneously Total of 18 cycles on treatment or early discontinuation. |
研究衡量的是什么?
主要结果指标
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Number of Participants In Best Hematological Response Categories as Determined by the Investigator Using International Working Group 2000 (IWG 2000) Criteria For Myelodysplastic Syndromes (MDS) During the Initial Study Period.
大体时间:Day 1 (randomization) to 6 months
|
Participant counts by best hematological response; complete remission(CR) is better than a partial remission(PR) which is better than stable disease(SD). Investigator determined responses followed IWG 2000 criteria for MDS CR: repeat bone marrow show <5% myeloblasts, and peripheral blood evaluations lasting >=2 months of hemoglobin(>110 g/L), neutrophils(>=1.5x10^9/L), platelets(>=100x10^9/L), blasts (0%) and no dysplasia PR is the same as CR for peripheral blood: bone marrow shows blasts decrease by >=50% or a less advanced FAB classification from pretreatment (see Population Descrip) |
Day 1 (randomization) to 6 months
|
|
Number of Participants With Best Hematological Improvement Derived Using International Working Group 2000 (IWG 2000) Criteria for MDS During the Initial Study Period.
大体时间:Day 1 (randomization) to 6 months
|
IWG 2000 Criteria: Pretreatment=hemoglobin <110g/L or RBC transfusion-dependence, platelet count <100x10^9/L or platelet transfusion dependence, absolute neutrophil count <1.5x10^9/L. Erythroid response: Major->20g/L increase in hemoglobin or transfusion independence. Minor- 10-20g/L increase in hemoglobin or >=50% decrease in transfusion requirements. Platelet response: Major-absolute increase of platelet count by >=30x10^9/L or platelet transfusion independence. Minor->=50% increase in platelet count with net increase >10x10^9/L but <30x10^9/L. (continued in Population Description) |
Day 1 (randomization) to 6 months
|
|
Number of Participants With Overall Best Hematologic Response and Hematologic Improvement Based on IWG 2000 Criteria For MDS During the Initial Study Period
大体时间:Day 1 (randomization) to 6 months
|
Number of participants whose best hematological outcome was either complete remission (CR), partial remission (PR) (as determined by the investigator), or any hematologic improvement (based on the IWG 2000 criteria for MDS).
See previous outcomes for detailed definitions.
|
Day 1 (randomization) to 6 months
|
|
Number of Participants Who Improved or Maintained The Hematologic Response From the Initial Study Period (Based on IWG 2000 Criteria For MDS) During the Maintenance Period
大体时间:24 months
|
Hematologic response during the maintenance period are compared to the response in the initial study period.
Initial response could have been a complete remission, a partial remission, stable disease or a hematologic improvement.
Maintenance period best response is after randomization to a maintenance arm for those randomized, and is after the start of cycle 7 for those remaining on initial period treatment throughout the study.
|
24 months
|
次要结果测量
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Baseline Hemoglobin Values
大体时间:Day 1 (randomization)
|
The median values for hemoglobin based on blood tests performed on study day 1 (prior to study treatment) constitute a baseline measure for hemoglobin.
Baseline values are used to compare to values following treatment.
|
Day 1 (randomization)
|
|
Change From Baseline in Hemoglobin at End of Initial Study Period (6 Months)
大体时间:6 months
|
The difference between hemoglobin values at the end of the initial study period minus the hemoglobin values at baseline.
|
6 months
|
|
Change From Baseline in Hemoglobin at the End of the Maintenance Study Period
大体时间:24 months
|
The difference between hemoglobin values at the end of the maintenance study period minus the hemoglobin values at baseline.
|
24 months
|
|
Baseline Platelet Values
大体时间:Day 1 (randomization)
|
The median values for platelets based on blood tests performed on study day 1 (prior to study treatment) constitute a baseline measure for platelets.
Baseline values are used to compare to values following treatment.
|
Day 1 (randomization)
|
|
Change From Baseline in Platelets at the End of Initial Study Period (6 Months)
大体时间:6 months
|
The difference between platelet values at the end of the initial study period minus the platelet values at baseline.
|
6 months
|
|
Change From Baseline in Platelets at the End of the Maintenance Study Period (Month 24)
大体时间:24 months
|
The difference between platelet values at the end of the maintenance study period minus the platelet values at baseline.
|
24 months
|
|
Baseline Absolute Neutrophil Count (ANC) Values
大体时间:Day 1 (randomization)
|
The median values for ANC based on blood tests performed on study day 1 (prior to study treatment) constitute a baseline measure for ANC.
Baseline values are used to compare to values following treatment.
|
Day 1 (randomization)
|
|
Change From Baseline in Absolute Neutrophil Count (ANC) at the End of Initial Study Period (6 Months)
大体时间:6 months
|
The difference between ANC values at the end of the initial study period minus the ANC values at baseline.
|
6 months
|
|
Change From Baseline in Absolute Neutrophil Count (ANC) at the End of the Maintenance Study Period (Month 24)
大体时间:24 months
|
The difference between ANC values at the end of the maintenance study period minus the ANC values at baseline.
|
24 months
|
|
Red Blood Cell (RBC) Transfusion Status at Baseline and End of Initial Study Period (6 Months)
大体时间:6 months
|
Shift table comparing the RBC transfusion status of patients at the end of the initial study period to the transfusion status at baseline.
|
6 months
|
|
Platelet Transfusion Status at Baseline and End of Initial Study Period (6 Months)
大体时间:6 months
|
Shift table comparing the platelet transfusion status of patients at the end of the initial study period to the transfusion status at baseline.
|
6 months
|
|
Red Blood Cell (RBC) Transfusion Status at Baseline and End of Maintenance Study Period (24 Months)
大体时间:24 months
|
Shift table comparing the RBC transfusion status of patients at the end of the maintenance study period to the transfusion status at baseline.
|
24 months
|
|
Platelet Transfusion Status at Baseline and End of Maintenance Study Period (24 Months)
大体时间:24 months
|
Shift table comparing the platelet transfusion status of patients at the end of the maintenance study period to the transfusion status at baseline.
|
24 months
|
|
Change From Baseline in the Number of Infections Requiring Treatment With IV Antibiotics Per Treatment Cycle (28 Days) for the Initial Study Period
大体时间:6 months
|
Baseline uses the average number of infections requiring IV antibiotic treatment from the 28 days prior to and including the day of first dose to an initial treatment arm.
Initial study period values total the number of infections requiring IV antibiotic treatment divided by the number of treatment cycles (each cycle is approximately one month).
|
6 months
|
|
Change From Baseline in the Number of Infections Requiring Treatment With IV Antibiotics Per Treatment Cycle (28 Days) for the Maintenance Study Period
大体时间:24 months
|
Baseline uses the average number of infections requiring IV antibiotic treatment from the 28 days prior to and including the day of first dose to an initial treatment arm.
Maintenance study period values total the number of infections requiring IV antibiotic treatment divided by the number of treatment cycles (each cycle is approximately one month).
|
24 months
|
合作者和调查者
赞助
调查人员
- 研究主任:CL Beach、Celgene Corporation
出版物和有用的链接
一般刊物
- R. Lyons, et al. Rapid onset of effectiveness with three alternative azacitidine (aza) dosing regimens in patients (pts) with myelodysplastic syndromes (MDS). Haematologica 2008;93(suppl 1):Abs.0232.
- Lyons R, et al. Tolerability and hematologic improvement assessed using three alternative dosing schedules of azacitidine in patients with myelodysplastic syndromes. Presented at the 2007 ASCO Annual Meeting, June 1-5, 2007, Chicago, IL. Abstract No. 7083
- Komrokji R, Swern AS, Grinblatt D, Lyons RM, Tobiasson M, Silverman LR, Sayar H, Vij R, Fliss A, Tu N, Sugrue MM. Azacitidine in Lower-Risk Myelodysplastic Syndromes: A Meta-Analysis of Data from Prospective Studies. Oncologist. 2018 Feb;23(2):159-170. doi: 10.1634/theoncologist.2017-0215. Epub 2017 Nov 8.
研究记录日期
研究主要日期
学习开始 (实际的)
初级完成 (实际的)
研究完成 (实际的)
研究注册日期
首次提交
首先提交符合 QC 标准的
首次发布 (估计)
研究记录更新
最后更新发布 (实际的)
上次提交的符合 QC 标准的更新
最后验证
更多信息
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.